Cardiovascular stents - Biomaterials and Devices for the Circulatory System - page 192

results were obtained from a single layer coating model using
PEVA : PBMA : Paclitaxel (Levy et al. , 2009).
First generation stents, which successfully achieved the controlled release
of sirolimus or paclitaxel from durable polymer coatings, were proven to
be effective in reducing angiographic restenosis and the need for re-inter-
vention (Table 7.1). DESs loaded with anti-proliferative drugs were shown
to minimise the proliferation of smooth muscle cells and reduce restenosis
and rates of target lesion revascularisation by up to 70% compared with
bare metal stents (Serruys, et al. , 2006b). However, more recent opinion is
beginning to question the clinical effi cacy of these DESs, in particular their
safety in relation to an increased risk in late stent thrombosis and death by
heart infarction (Bavry et al. , 2006; Daemen et al. , 2007; Stone et al. , 2007;

Table 7.1 Examples of drug eluting stents, manufacturers, materials and
coatings (adapted from Fischell et al. , 2009)

Stent name &
manufacturer Drug Stent material Coating

Sirolimus Cypher, Cypher

Select; Cordis
Corporation

Stainless steel Parylene C primer,

followed by a mixture
of polyethylene-co-
vinyl acetate (PEVA)
and poly n -butyl
methacrylate (PBMA)

Cardiomind;
Cardiomind
Inc.

Nitinol Polylactic acid (PLA) +

poly(lactide-co-
glycolide) (PLGA)

Excel; JW
Medical
Systems Ltd

Stainless steel Polylactic acid (PLA)

Nevo; Cordis
Corporation

Cobalt-
chromium

Poly(lactide-co-
glycolide) (PLGA)

￿ ￿ ￿ ￿ ￿

Cura;
OrbusNeich

Stainless steel Polylactic acid (PLA) +

poly(lactide-co-
glycolide) (PLGA)

Supralimus;
Sahajanand
Medical
Technologies
Pvt. Ltd

Stainless steel Poly- L -lactic acid (PLLA)

+ poly(lactide-co-

glycolide) (PLGA)

polyvinyl pyrrolidone
(PVP)

+

Yukon;
Translumina
GmbH

Stainless steel
316LVM with
surface
micropores

None

Vestasync; MIV
Therapeutics
Inc.

Stainless steel Hydroxapatite lipid

+